Literature DB >> 10614984

Comparison of the responses of B1 and B2 kinin receptors to agonist stimulation.

A Faussner1, J M Bathon, D Proud.   

Abstract

The human B2 kinin receptor (B2KR), stably expressed in Chinese hamster ovary cells, responded to bradykinin stimulation with rapid (within minutes) ligand internalization and loss of cell surface receptors (sequestration). By contrast, B1 kinin receptors (B1KR) showed almost no ligand internalization or receptor sequestration upon stimulation with des-Arg10-Kallidin (DAK). The ability of the B2KR to internalize and sequester is conferred by information in the cytoplasmic tail of the receptor. It is normally impossible to determine receptor affinity at 37 degrees C because of internalization and sequestration processes. We created a mutant B2KR, truncated at K315 of the cytoplasmic tail, that was no longer able to internalize or sequester, and compared the affinity of this mutant, and of the B1KR, at 0 degrees C and 37 degrees C. The B1KR receptor showed the same affinity (Kd = 0.4 nM) at both 0 degrees C and 37 degrees C. By contrast, the K315 mutant of the B2KR showed a lower affinity (Kd = 2.9 nM) at 37 degrees C than at 0 degrees C (Kd = 1.4 nM), indicating more rapid ligand dissociation at 37 degrees C. After ligand exposure, clones expressing B1KR exhibited a very slow dissociation of DAK, even at 37 degrees C. Although both kinin receptor subtypes induce the generation of inositol phosphates, functional responses showed clear differences. The response to stimulation of the B2KR comprises a rapid loss of functional responses, receptor sequestration, and ligand dissociation, and, upon long term stimulation, downregulation. By contrast, ligand stimulation of the B1KR, once this receptor is expressed de novo under pathological conditions, results in persistent signaling due to lack of ligand dissociation, desensitization and receptor sequestration. Moreover, long term stimulation of this receptor actually leads to increased expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10614984     DOI: 10.1016/s0162-3109(99)00052-1

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  7 in total

1.  Helix 8 plays a crucial role in bradykinin B(2) receptor trafficking and signaling.

Authors:  Jens Feierler; Markus Wirth; Benjamin Welte; Steffen Schüssler; Marianne Jochum; Alexander Faussner
Journal:  J Biol Chem       Date:  2011-10-20       Impact factor: 5.157

Review 2.  Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes.

Authors:  João B Calixto; Rodrigo Medeiros; Elizabeth S Fernandes; Juliano Ferreira; Daniela A Cabrini; Maria M Campos
Journal:  Br J Pharmacol       Date:  2004-11-01       Impact factor: 8.739

3.  Endotoxin sensitization to kinin B(1) receptor agonist in a non-human primate model: haemodynamic and pro-inflammatory effects.

Authors:  D deBlois; R A Horlick
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  Interactions between carboxypeptidase M and kinin B1 receptor in endothelial cells.

Authors:  Paola Bianchi Guimarães; Rafael Filippelli da Silva; Carolina Caldas Hoff; Liliam Fernandes; Clovis Ryuichi Nakaie; Jair Ribeiro Chagas; Adriana Karaoglanovic Carmona; Michael Bader; João Bosco Pesquero
Journal:  Inflamm Res       Date:  2019-06-19       Impact factor: 4.575

5.  Reversal of pulmonary arterial hypertension and neointimal formation by kinin B1 receptor blockade.

Authors:  Dileep Reddy Rampa; Priya Murugesan; Honglu Chao; Huiying Feng; Wenxin Dai; Dongwon Lee; Anton Pekcec; Henri Doods; Dongmei Wu
Journal:  Respir Res       Date:  2021-10-30

6.  A role for G-proteins in directing G-protein-coupled receptor-caveolae localization.

Authors:  Rhodora Cristina Calizo; Suzanne Scarlata
Journal:  Biochemistry       Date:  2012-11-14       Impact factor: 3.162

7.  Novel kinin B₁ receptor splice variant and 5'UTR regulatory elements are responsible for cell specific B₁ receptor expression.

Authors:  Faang Y Cheah; Svetlana Baltic; Suzanna E L Temple; Kanti Bhoola; Philip J Thompson
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.